The CEO of an innovative Welsh tech company behind a “life-changing” continuous blood glucose monitor was on hand to showcase the device at the Wales Investment Summit.
Sabih Chaudhry represented Afon Technology at the prestigious event in Newport yesterday (Monday, December 1, 2025), where more than 300 industry and business leaders from around the world gathered to explore potential investment opportunities across Wales.
His Royal Highness The Prince of Wales, Prince William, also addressed attendees during the Summit, highlighting the wealth of investment opportunities available across Wales. Based in Monmouthshire, Afon Technology was chosen as one of a select number of Welsh innovators invited to attend.
The invitation recognises the company’s creation of the world’s first non-invasive, real-time continuous blood glucose sensor – a development poised to significantly improve life for people living with diabetes.
Afon Technology’s device, Glucowear™, offers a needle-free way to monitor blood glucose levels continuously, providing a more comfortable and convenient alternative for diabetes management.
Sabih Chaudhry said: “Being invited to the Wales Investment Summit is a real testament to the hard work and vision of the team at Afon Technology. Glucowear™ represents more than just a breakthrough in diabetes care, it is a step towards giving people freedom from the daily burdens of glucose monitoring.” He added: “Engaging with investors and industry leaders here in Newport has reinforced our belief that Welsh innovation can have a global impact. We are excited to continue pushing the boundaries of medical technology and to bring solutions to people that are truly life changing.”
The Wales Investment Summit is an international event that showcases Wales as a destination for global investment, connecting investors, business leaders and Welsh companies to drive economic growth, innovation and job creation.
Afon Technology is a leading innovator in wearable healthcare technology, dedicated to developing cutting-edge solutions that improve patient outcomes and quality of life.
Unlike the current continuous glucose monitoring devices, Glucowear™ will measure blood glucose levels in real-time without the need to penetrate the skin at all, making it easier to manage the condition, reducing the risk of diabetes-related complications such as heart attack, stroke, blindness, kidney failure and limb amputations.
Companies such as Apple, Samsung and Google are rumoured to have been trying to develop non-invasive blood glucose monitoring, but so far none have been successful. Afon Technology hopes to win the race to this important milestone.
Preliminary clinical research gives people with diabetes hope that such a device could become a reality in the near future.
